Phase I trial of stereotactic body radiotherapy with concurrent fixed dose tyrosine kinase inhibitors in metastatic renal carcinoma : dose limiting toxicity and abscopal effect Ghent University
Patients with kidney cancer that has spread, are often treated with the tyrosine kinase inhibitor substance (TKR). This substance acts targeted by the growth of the tumor cells and the blood vessels to the tumor to slow down. This treatment often works only temporarily, and some patients do not respond to. The aim of the study is to investigate whether the effect of TKR is stronger in combination with a highly-oriented (= stereotactic) ...